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tests were used to identify differences between GLAR or NPH and DET for continuous 
and categorical variables respectively. A Wilcoxon rank sum test was used to identify
differences in mean DACON between GLAR or NPH and DET. RESULTS: Of the
21,881 patients identiﬁ ed, 2215 (10.1%) were treated with DET, 16,548 (75.6%) with 
GLAR, and 3118 (14.3%) with NPH. A higher percentage of NPH users were above
65 years (42.4%) compared to GLAR (35.2%) and DET (31.2%) (p  .001). Mean/
median DACON as units/day were 35/26 for DET, 32/27 for GLAR (p  0.06) and 
41/32 for NPH (p  .001). A higher percentage of DET patients had prior antidiabetic
use compared to GLAR and NPH users (75.8%, 67.8% 52.3% respectively, p  .001). 
The percentage using multiple antidiabetic agents before the observation period was 
highest for DET (56.3%), followed by GLAR (45.7%) and NPH (29.5%) (p  .001).
CONCLUSIONS: DACON was highest with NPH and did not vary between DET
and GLAR. A greater proportion of DET patients were treated with multiple antidia-
betic agents prior to insulin start, suggesting more severe diabetes.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported 
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OBJECTIVES: To examine the effect of medication choice between duloxetine and 
pregabalin on medication compliance outcomes among patients with diabetic periph-
eral neuropathic pain (DPNP). METHODS: A retrospective cohort study design was
used with a large US national commercial health care claims database over 2005–
2007. Patients aged 18–64 who dispensed duloxetine or pregabalin in 2006 were
selected, with the ﬁ rst dispense date as the “index date.” All individuals included were
diagnosed with DPNP in the 12-month pre-index period, and continuously enrolled 
in both the 12 months pre- and post-index periods. Duloxetine and pregabalin cohorts 
were constructed based on the initial agent. Propensity score analysis was used to 
control for cross-cohort differences in demographics, pre-index clinical and economic
characteristics, and pre-index treatment patterns. Medication compliance outcomes
were examined between cohorts via medication possession ratio (MPR) and pro-
portion of patients with MPR q 80%. RESULTS: Both the duloxetine (n  603) and 
pregabalin (n  1,751) cohorts had the mean age around 55 years (54.9 vs. 55.6).
Many duloxetine and pregabalin patients had cardiovascular disease (86.9% vs.
89.0%), neuropathic pain other than DPNP (80.3% vs. 83.2%), hypertension (78.8% 
vs. 82.6%), osteoarthritis (52.2% vs. 53.1%), and used anticonvulsants (36.3% vs. 
35.6%) and opioids (32.2% vs. 28.4%). Controlling for demographics, pre-index 
clinical and economic characteristics, and prior medication history, duloxetine patients 
had signiﬁ cantly higher MPR than pregabalin patients (75.8% vs. 52.9%, p  0.05). 
The proportion of patients with MPR q 80% was also signiﬁ cantly higher among 
patients in the duloxetine cohort (47.4% vs. 27.6%, p  0.05). CONCLUSIONS: In
a real world setting, medication compliance measured by MPR or proportion of 
patients with MPR q 80% was statistically signiﬁ cantly higher among DPNP patients 
treated with duloxetine than those on pregabalin. The results suggest that medication
choices between duloxetine and pregabalin had statistically signiﬁ cant effects on 
medication compliance outcomes.
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OBJECTIVES: To evaluate patterns of medication use in Type II diabetes patients and
to assess risk factors associated with non-adherence/non-persistence to drug therapy. 
METHODS: Administrative claims data (2003–2006) were used to identify newly
diagnosed patients aged q30 years with at least one oral antidiabetic(OAD) prescrip-
tion. Patterns of medication use(augmentation, switch, gap) were evaluated. Medica-
tion possession ratio(MPR) 0.8 and proportion of days covered(PDC) 0.8 were
deﬁ ned as non-adherence to the index and any OAD medication, respectively. Persis-
tence was assessed for medication discontinuation(gap q 90 days) and time to discon-
tinuation. Logistic regression and Cox models were performed to investigate signiﬁ cant 
factors of non-adherence/non-persistence. RESULTS: A total of 7799 patients were 
identiﬁ ed. Patients initiated on biguanides(16%) were less likely to augment with
another drug as compared to those on other medications(19%, p  0.0001). Patients 
on ﬁ xed dose medication(FDM) thiazolidinedione & biguanide were more likely to
switch(26%) and discontinue(64%), but less likely to experience a gap(37%) as com-
pared to other medication cohorts(a5% for switch, a45% for discontinuation, and 
q38% for gap). They were also least adherent to their index drug(16%), but their 
adherence rate to any OAD medication increased to 42%. Signiﬁ cant variables 
associated with non-adherence/discontinuation of drug therapy included younger age 
(65 years) (OR  5.19 vs. q65 years, HR  0.98, for non-adherence and discontinu-
ation, respectively), fewer number of drugs taken (OR  0.95, HR  0.98), female 
(OR  1.34, HR  1.19), initiation on monotherapy or FDM(OR  1.62, HR  1.39), 
and increasing comorbidity(OR  1.20, HR  1.22). Signiﬁ cant factors also associated 
with discontinuation included not augmenting(HR  0.83), switching medications(HR 
 2.64), and no medication gap(HR  0.23). CONCLUSIONS: Index medication 
played an important role in medication compliance based on non-adherence and
non-persistence measures. Intervention/disease management programs designed to 
improve medication compliance should be tailored according to index medication, 
especially for those initiated on FDM thiazolidinedione & biguanide, for which
patients displayed less optimal medication use patterns and were more likely to dis-
continue drug therapy.
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OBJECTIVES: The objective of the current study is to explore the impact of treatment
complexity on patient behavior and subsequent glycemic control among type 2
diabetics (T2DM). METHODS: This was a retrospective evaluation of T2DM patients
continuously enrolled in a national health plan during 2000–2007. Patients with a 
T2DM diagnosis, naïve to OADs, and not using insulin were included. A treatment 
complexity score was assigned based on dosage form, usage frequency, and special 
directions (e.g. with food, time of day) with higher values indicating higher complexity.
Adherence was calculated as a medication possession ratio (MPR) weighted by time
on each OAD during a 1-year period. Baseline and follow-up A1c values were obtained 
for those with laboratory data. Logistic and linear multivariate regressions were con-
ducted, controlling for patient demographics, baseline A1c and comorbidities. 
RESULTS: A total of 94,860 patients were identiﬁ ed, 16,198 with A1c values.
Mean age was 52.6 years, 55% male, 78% initiated on monotherapy (48% metfor-
min, 17% sulfonylurea), and 20% initiated on 2 OADs. Mean treatment complexity 
score was 3.33 (range 0–14), 29% were considered low complexity (0–2 points), 57% 
medium complexity (2–5), and 14% high complexity (5). Mean 1-year adherence 
to OAD therapy was 75%, 73% and 69% for low, medium and high complexity. 
After controlling for confounders, the odds of being adherent (MPR q 80%) were 
19% and 43% lower for medium and high complexity, versus low complexity regi-
mens (p  0.0001). Mean baseline and follow-up A1c values were 8.20% and 6.56%. 
After controlling for confounders, follow-up A1c values were predicted to be 0.36% 
lower among adherent patients than non-adherent patients. CONCLUSIONS: The 
complexity of diabetes treatments has negative effects on adherence, which results in 
poor glycemic control. Less complex diabetes treatments (i.e. less dosing frequency 
and no special directions) may offer improvements in patient adherence and subse-
quent A1c values.
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OBJECTIVES: Hybrid applications of conventional exact covariate matching and 
propensity score concepts have recently been explored in the literature. In this research, 
we examine the advantages and disadvantages of hybrid usage of these two principles.
Speciﬁ cally, we evaluate the impact on comparable samples and treatment persistence
measures from retrospective prescription claims data. METHODS: Patient persistence 
on anti-diabetic agents (Exenatide and Insulin Glargine) was used to compare six 
hybrid matching algorithms proposed by Yang and Stemkowski (2008), using 
IMS’ LifeLink longitudinal prescription database (LRx). Persistence was evaluated
by persistent days on quartiles, persistence rate over time, survival censoring
rate, Kaplan-Meier survival curves and Cox Proportional Hazard Model. The 
hybrid matching algorithms were compared on run time, matching rate and bias 
reduction. RESULTS: Directly matched cohorts resulted in more comparable
samples and improved the evaluation on treatment persistence relative to pre-matched 
sample. When propensity score played as a caliper, the matching process resulted
in un-balanced variables and exhibited the weakest ability in bias correction due 
to the least drop in standardized difference. This was the only method among the 
six that failed assumption tests in the survival analysis (P  0.05). Conversely, among 
all other algorithms where all factors were balanced, the algorithm in which pro-
pensity score acted in a parenting role had the least running time and greatest 
bias reduction, which was displayed by the largest decline in standardized difference.
The smallest values in Fit-of-Statistics through the whole study period also indicated 
the strongest hold of assumptions in the Cox proportional hazard model, relative 
to the other ﬁ ve algorithms. CONCLUSIONS: In the assessment of treatment 
persistence through survival analysis, the role of propensity score as a parenting
factor in the selection of matched samples outperformed alternative hybrid match-
ing algorithms. In contrary, use of propensity score as a caliper factor, was least
satisfactory.
